Actively Recruiting
Study of Enasidenib Treatment for Adults with IDH2-Mutant Angioimmunoblastic T-Cell Lymphoma with Rituximab Combination Option
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-08-04
25
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety of enasidenib as a treatment for adults with angioimmunoblastic T-cell lymphoma AITL that has an IDH2 mutation. This study focuses on patients whose lymphoma has relapsed or progressed after previous systemic therapy. The study aims to understand how safe enasidenib is when given alone or combined with rituximab in this patient group. Participants will receive oral enasidenib at a dose of 100 mg daily in 28-day treatment cycles. For those showing co-occurring B-cell lymphoproliferation, intravenous rituximab will be given weekly for the first month, then monthly for three months, totaling four months of rituximab treatment. If B-cell proliferation persists after four months, rituximab treatment will continue monthly until no such evidence remains. Throughout the study, participants will be monitored for treatment response over one year, focusing on the response rate. Monitoring includes laboratory tests and clinical assessments to evaluate safety and disease status. Participants need to adhere to the study visit schedule and protocol requirements, with the study lasting until December 2027.
CONDITIONS
Brief Title
A Study of Enasidenib in People With T-Cell Lymphoma
Research Team
Z
Zachary Epstein-Peterson, MD
S
Steven Horwitz, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
